BeiGene poised to disrupt market

Posted 25 January 2023 AM

BeiGene is looking to kick off the year with a major new indication for Brukinsa that could disrupt the blood cancer market in Australia.

Brukinsa belongs to a class of drugs known as BTK inhibitors, which includes Janssen's Imbruvica and AstraZeneca's Calquence.

To see the whole article, please login

Popular

Latest Jobs

Pharma in Focus Jobs

MORE NEWS

Email this article to a friend

From:

Subject

Friend's email

Message to go with the article

Print this article

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Retype password

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.

Skip password for now